169 related articles for article (PubMed ID: 16086650)
1. Treatment of dyslipidaemia in HIV-infected persons.
Manuel O; Thiébaut R; Darioli R; Tarr PE
Expert Opin Pharmacother; 2005 Aug; 6(10):1619-45. PubMed ID: 16086650
[TBL] [Abstract][Full Text] [Related]
2. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
Llibre JM; Domingo P; Palacios R; Santos J; Pérez-Elías MJ; Sánchez-de la Rosa R; Miralles C; Antela A; Moreno S;
AIDS; 2006 Jun; 20(10):1407-14. PubMed ID: 16791015
[TBL] [Abstract][Full Text] [Related]
3. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.
Negredo E; Moltó J; Puig J; Cinquegrana D; Bonjoch A; Pérez-Alvarez N; López-Blázquez R; Blanco A; Clotet B; Rey-Joly C
AIDS; 2006 Nov; 20(17):2159-64. PubMed ID: 17086055
[TBL] [Abstract][Full Text] [Related]
4. Single nucleotide polymorphisms in LCAT may contribute to dyslipidaemia in HIV-infected individuals on HAART in a Ghanaian population.
Bani SB; Danquah KO; Obirikorang C; Owiredu WKBA; Quaye L; Muonir Der E; Acheampong E; Adams Y; Dapare PPM; Banyeh M; Anto EO; Sakyi SA
Sci Rep; 2020 Nov; 10(1):19419. PubMed ID: 33173066
[TBL] [Abstract][Full Text] [Related]
5. Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals: a randomized trial.
Lazzaretti RK; Kuhmmer R; Sprinz E; Polanczyk CA; Ribeiro JP
J Am Coll Cardiol; 2012 Mar; 59(11):979-88. PubMed ID: 22402068
[TBL] [Abstract][Full Text] [Related]
6. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
7. Dyslipidaemia associated with the highly active antiretroviral therapy in AIDS patient: reversion after switching (stavudine to tenofovir and lopinavir/ritonavir to atazanavir/ritonavir).
Domingos H; da Cunha RV; Paniago AM
Braz J Infect Dis; 2007 Apr; 11(2):290-2. PubMed ID: 17625780
[TBL] [Abstract][Full Text] [Related]
8. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.
Calza L; Manfredi R; Colangeli V; Tampellini L; Sebastiani T; Pocaterra D; Chiodo F
AIDS; 2005 Jul; 19(10):1051-8. PubMed ID: 15958836
[TBL] [Abstract][Full Text] [Related]
9. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
[TBL] [Abstract][Full Text] [Related]
10. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
Calza L; Manfredi R; Chiodo F
J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
[TBL] [Abstract][Full Text] [Related]
11. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management.
Calza L; Manfredi R; Chiodo F
Int J Antimicrob Agents; 2003 Aug; 22(2):89-99. PubMed ID: 12927947
[TBL] [Abstract][Full Text] [Related]
12. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection.
Koppel K; Bratt G; Eriksson M; Sandström E
Int J STD AIDS; 2000 Jul; 11(7):451-5. PubMed ID: 10919487
[TBL] [Abstract][Full Text] [Related]
13. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
Viganò A; Aldrovandi GM; Giacomet V; Merlo M; Martelli L; Beretta S; Luraschi P; Rombolà G; Mora S
Antivir Ther; 2005; 10(8):917-24. PubMed ID: 16430197
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.
Riddler SA; Li X; Chu H; Kingsley LA; Dobs A; Evans R; Palella F; Visscher B; Chmiel JS; Sharrett A
HIV Med; 2007 Jul; 8(5):280-7. PubMed ID: 17561873
[TBL] [Abstract][Full Text] [Related]
15. Lipid management in patients who have HIV and are receiving HIV therapy.
Aberg JA
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):207-22. PubMed ID: 19217520
[TBL] [Abstract][Full Text] [Related]
16. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
Calza L; Manfredi R; Pocaterra D; Chiodo F
J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular implications of HIV-induced dyslipidemia.
Giannarelli C; Klein RS; Badimon JJ
Atherosclerosis; 2011 Dec; 219(2):384-9. PubMed ID: 21722900
[TBL] [Abstract][Full Text] [Related]
18. Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients.
Calza L; Colangeli V; Manfredi R; Bon I; Re MC; Viale P
J Antimicrob Chemother; 2016 Jun; 71(6):1451-65. PubMed ID: 26846208
[TBL] [Abstract][Full Text] [Related]
19. HAART-associated dyslipidemia varies by biogeographical ancestry in the multicenter AIDS cohort study.
Nicholaou MJ; Martinson JJ; Abraham AG; Brown TT; Hussain SK; Wolinsky SM; Kingsley LA
AIDS Res Hum Retroviruses; 2013 Jun; 29(6):871-9. PubMed ID: 23343448
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy.
Rahman AP; Eaton SA; Nguyen ST; Bain AM; Payne KD; Bedimo R; Busti AJ
Pharmacotherapy; 2008 Jul; 28(7):913-9. PubMed ID: 18576906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
